Overview

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Status:
Terminated

Trial end date:
2014-03-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy. Specifically, the goal is to demonstrate the superiority of this combination compared with an active comparator arm (investigator's choice of rituximab+bendamustine or rituximab+gemcitabine) using the primary endpoint of overall survival.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Collaborator:

UCB Pharma

Treatments:

Bendamustine Hydrochloride
Gemcitabine
Inotuzumab Ozogamicin
Rituximab